- Home
- TACT vs CUE Comparison
TACT vs CUE Comparison
Compare TACT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- CUE
- Stock Information
- Founded
- TACT 1996
- CUE 2014
- Country
- TACT United States
- CUE United States
- Employees
- TACT N/A
- CUE N/A
- Industry
- TACT Computer peripheral equipment
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- CUE Health Care
- Exchange
- TACT Nasdaq
- CUE Nasdaq
- Market Cap
- TACT 51.0M
- CUE 61.1M
- IPO Year
- TACT 1996
- CUE 2018
- Fundamental
- Price
- TACT $4.66
- CUE $0.82
- Analyst Decision
- TACT Strong Buy
- CUE Strong Buy
- Analyst Count
- TACT 1
- CUE 2
- Target Price
- TACT $5.00
- CUE $3.00
- AVG Volume (30 Days)
- TACT 51.9K
- CUE 283.3K
- Earning Date
- TACT 11-06-2025
- CUE 11-13-2025
- Dividend Yield
- TACT N/A
- CUE N/A
- EPS Growth
- TACT N/A
- CUE N/A
- EPS
- TACT N/A
- CUE N/A
- Revenue
- TACT $47,949,000.00
- CUE $8,286,000.00
- Revenue This Year
- TACT $21.67
- CUE N/A
- Revenue Next Year
- TACT $7.63
- CUE N/A
- P/E Ratio
- TACT N/A
- CUE N/A
- Revenue Growth
- TACT N/A
- CUE N/A
- 52 Week Low
- TACT $3.12
- CUE $0.54
- 52 Week High
- TACT $5.70
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- TACT 40.08
- CUE 56.92
- Support Level
- TACT $4.53
- CUE $0.76
- Resistance Level
- TACT $5.26
- CUE $0.96
- Average True Range (ATR)
- TACT 0.34
- CUE 0.06
- MACD
- TACT -0.12
- CUE 0.01
- Stochastic Oscillator
- TACT 9.39
- CUE 46.76
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.